

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/624,884	
	Filing Date	July 22, 2003	
	First Named Inventor	HARKINS, Richard et al.	
	Art Unit	1643	
	Examiner Name	BLANCHARD, David J.	
Total Number of Pages in This Submission	3	Attorney Docket Number	61791AUSC1

RECEIVED
CENTRAL FAX CENTER
MAY 19 2006

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	BERLEX BIOSCIENCES	
Signature	<i>Wendy L. Washtien</i>	
Printed name	WENDY L. WASHTIEN, PH.D.	
Date	May 19, 2006	Reg. No. 36,301

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature	<i>M. Flores</i>	
Typed or printed name	MARY ANN FLORES	Date May 19, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/624,884

Casc 51791AUSC1

RECEIVED
CENTRAL FAX CENTER

MAY 19 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
Harkins et al. :
Serial No. 10/624,884 : Group Art Unit 1643
Filed July 22, 2003 : Examiner: David J. Blanchard
For DNA ENCODING A NOVEL RG1 POLYPEPTIDE

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

This communication is in response to the Restriction Requirement dated
May 3, 2006.

The Examiner has required restriction to one of the following groups:

- Group I. Claims 1-25, drawn to an antibody and immunoconjugate that binds an RG1 polypeptide.
- Group II. Claim 26, drawn to a method of selectively destroying RG1 expressing cells with an immunoconjugate that binds the RG1 polypeptide.
- Group III. Claims 27-29, drawn to a method of treating a disease in a human patient, wherein the disease is associated with expression of an RG1 polypeptide

51791AUSC1rr

10/624,884

2

51791AUSC1

comprising administering an immunoconjugate that binds RG1 polypeptide.


Group IV. Claims 30-35, drawn to a method of detecting a disease associated with the expression of an RG1 polypeptide in a subject comprising administering an RG1 specific immunoconjugate, detecting binding of the immunoconjugate and determining the level of binding of the immunoconjugate compared with the level of binding in disease-free subjects.

Applicants elect Group I, Claims 1-25, drawn to an antibody and immunoconjugate that bind to an RG1 polypeptide. Should these product claims be found allowable, the withdrawn process claims should be rejoined.

Applicants reserve the right, under 35 U.S.C. 120, to pursue the non-elected subject matter of Groups II-IV in separate divisional applications.

This response is timely filed. Therefore, we believe no fee is due. However, the Commissioner is hereby authorized to charge deposit account 02-2117 for any fees necessary. This is not, however, authorization to charge the issue fee. Two copies of this paper are enclosed for this purpose.

Respectfully submitted,


Wendy L. Washtien, Ph.D.
Agent for Applicant
Reg. No. 36,301

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, CA 94804-0099
Telephone: (510) 262-5411
Fax: (510) 262-7095
Date: May 19, 2006

51791AUSC1rr